AMGN's anemia drug is losing ground as FDA now requires doc to prescribe less for dialysis patients and the evidence is clear Epo caused cardio and other problems. AMGN needs to do something for sure.
Now I know it is tough when greed puts $$$ in your eyes but why would AMGN buy AMRN? They are not in the cardiovascular pharma markets and would have to start from scratch in building a franchise that would need, for them, to have more products to justify. PFE or AZN make far more sense as they already have deep relationships developed which would allow them to have a bigger & more immediate impact.
I am amazed at all these investors being so down on AMRN developing their own franchise, KOS did very well and was bought for a good value (both sides)by ABT. You have KOS alumni with AMRN and I, for one, hope they own part of the product going forward to make sure it reaches the full potential. A truth, KOS was an excellent marketing & sales organization, don't assume such talent for all large pharmas have in the CDV market, sometimes they make money inspite of themselves (Merck & JNJ are examples).
I remember IDBE a number of years back with their spray application for the flu vaccine. Before it went bullistic with a buyout it went from $1.5ish to $5ish to $6ish to $9ish to $13ish all the way to $20ish, back to $9 - $10ish where it leveled out around $13ish for a few weeks. It then went charging for $20 and ended up being taken out at $30+ in very short order. My point is that if this is the real deal the stock will whip saw up and down to shake the "short timers" out as MM's pick up cheap shares. I predict this stock will return to the high teens in a couple of months then get whipsawed a few times befor being taken out in the mid $30's.....I have seen it before. The rise to new highs does not come without some bloodshed.